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LETTERS TO THE EDITORBLEEDING COMPLICATIONS
AFTER OFF-PUMP CORONARY
ARTERY BYPASS SURGERY:
INTERPRETING THE
CONTRIBUTION OF
HETASTARCH
To the Editor:
I read with interest the article by
Hecht-Dolnik and colleagues1 exam-
ining the association between intrao-
perative administration of hetastarch
and bleeding complications after off-
pump coronary artery bypass graft
surgery. The authors conclude that
administration of 1 L of hetastarch in
addition to albumin and crystalloid
versus albumin and crystalloid alone
resulted in increased risk of postopera-
tive transfusion requirement and chest
tube drainage. Given the existing body
of evidence showing an association
between greater quantitative blood
loss with the use of high molecular
weight (HMW) hetastarch compared
with both lower molecular weight he-
tastarch and albumin, in both car-
diac2,3 and noncardiac surgery,4,5 it is
not clear what further information
this study provides. Also, features of
the study design and ambiguity within
the manuscript itself both create diffi-
culty for a reader hoping to interpret
the validity or clinical significance of
these findings.
First, the composition of hetastarch
solution used in the study was never
specified. Choice of commercially
available hetastarch solutions in the
United States at the time this study
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saline or balanced salt solution. The
differing behavior of hetastarch solu-
tions related to their molecular weight,
degree of substitution, and electrolyte
composition has been a topic of fre-
quent investigation and commen-
tary.6-11 Unfortunately, failure of
Hecht-Dolnik and colleagues to better
identify the hetastarch used does not al-
low us to fully interpret their results.
Second, the reason for greater blood
loss and transfusion requirement is not
entirely clear. Standardized (protocol
or goal-directed) fluid administration
was not described in the methods and
presumably was not used during the
conduct of the study, nor does it appear
that the anesthesiologists administering
fluids during the case were blinded to
subject randomization. Not surpris-
ingly, the overall volume of colloid
was significantly greater in patients in
the hetastarch versus albumin group.
This greater overall colloid administra-
tion may have expanded plasma vol-
ume sufficiently to cause subsequently
greater clotting factor dilution, de-
creased blood viscosity, and increased
venous return and cardiac output. In
turn, these circulatory effects alone
may explain the increased chest tube
drainage and transfusion requirement
seen in the hetastarch group, irrespec-
tive of any specific influence hetastarch
may ormay not have had on platelet ag-
gregation or coagulation.12
Although transfusion requirement
certainly constitutes one clinically im-
portant end point, some equally com-
pelling secondary outcomes,
including length of ventilation, inten-
sive care unit stay and hospitalization,
rate of return to the operating room,
and survival to hospital discharge,
did not differ significantly. It would
have been interesting to know whether
thromboelastogram measurements
showed correlation with subsequent
transfusion requirement. Beyond that,
the opportunity was not taken to ex-
plore other physiologic consequences
reasonably attributable to fluid man-
agement. For example, effectiveof Thoracic and Cardiovascular Surgeplasma volume expansion with any
colloid, particularly hetastarch, may
improve microvascular perfusion and
tissue oxygenation, even at the cost
of greater quantitative blood loss.12-15
Therefore, a tradeoff between ap-
proaches may exist. Although the cho-
sen sample size may not have been
sufficient to find a difference between
measures indicative of tissue oxygena-
tion, their omission is nevertheless
unfortunate. The clinical importance
of plausibly relevant end points such
as infection, wound healing, organ
function, cognition, overall cost of
care, and longer-term mortality would
have justified their inclusion as sec-
ondary outcome variables.
Ultimately, clinical interventions
must be made with a balanced under-
standing and consideration of their
possible benefit and harm. The recent
availability of lower molecular weight
hetastarch solutions in the United
States, which exhibit lesser dose-de-
pendent coagulation impairment and
platelet inhibition, may eventually
lead to shift in practice away from
HMW hetastarch solutions altogether.
There will undoubtedly be more post-
marketing studies comparing these
newer hetastarch solutions to HMW
hetastarch and albumin. Unfortu-
nately, Hecht-Dolnik and colleagues1
studied only those end points that are
easily predicted and measured. I sin-
cerely hope that future investigative
efforts will encompass a more compre-
hensive set of clinically meaningful
end points, so that dollars and effort
spent on research will yield novel, in-
formative data that will be helpful in
guiding clinical decision-making.
Rachel Eshima McKay, MD
Associate Professor of Anesthesia and
Perioperative Care
University of California San
Francisco
San Francisco, CalifReferences
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We thank DrMcKay for her comments
regarding our article. We examined the
relative safety in off-pump coronary
artery bypass grafting (CABG) of
two volume replacement fluids in
widespread use at the time we con-
ducted our study.1 Dr McKay argues
that the questions we investigated are
moot, that the fluids whose safety we
investigated are not in widespread
contemporary use, and that there
were methodologic flaws in our study
conduct. We will now address each
of Dr McKay’s arguments, showing
that the choice between the volume re-
placement fluids we studied remains
clinically relevant, that her methodo-
logic concerns are overstated, and
that our findings raise a series of
further questions.
Dr McKay states that there is exist-
ing evidence demonstrating that use of
high molecular weight (HMW) hetas-
tarch, one of the fluids we studied, is
associated in both cardiac and noncar-
diac surgery with greater blood loss
than is either low molecular weight
(LMW) hetastarch or albumin. Dr
McKay offers two examples of prior
studies of bleeding risk in cardiac sur-
gery. Unfortunately, whereas we ex-
amined bleeding risk in off-pump
CABG, the first of the cardiac papers
Dr. McKay cites2 investigated the im-
pact of hetastarch and albumin as
pump prime in on-pump cardiac pro-
cedures, and the second3 examined
the impact of hydroxyethyl starch
(Voluven), an LMW hetastarch, in or-
thopedic procedures. Generalization
of findings from either of these studies
to the risk posed by HMW hetastarch
in off-pump procedures is at best prob-
lematic. The differences between the
hemodynamic properties of on-pump
versus off-pump cardiac procedures
are well documented.4-7 McKay also
cites two prior reviews of the risks as-
sociated with volume replacement
fluids in noncardiac surgery. The first8
cites 10 studies of volume replacement
that actually examined the effects of its
use in cardiac surgery. All of theseardiovascular Surgery c March 2010studies of cardiac surgery examined
on-pump procedures and/or other use
of fluids and/or postoperative fluid
administration. None of these studies
examined perioperative administration
of hetastarch versus albumin in off-
pump procedures. The second cited ar-
ticle9 again examined only on-pump
cardiac procedures. Perhaps DrMcKay
inadvertently switched the citations to
Gandhi3 and Wilkes9 and their associ-
ates. That second article9 was actually
one of the sparks for our decision to in-
vestigate risks associated with volume
replacement fluid use in off-pump pro-
cedures. Parenthetically, that second ar-
ticle is considered by many to have
established that the particular formula-
tion of hetastarch carries too high
a bleeding risk for it to be used routinely
for volume replacement in CABG pro-
cedures performed on-pump. We in-
stead examined the bleeding risk
carried by HMW hetastarch in off-
pump procedures. Approximately
20% of the CABG procedures in
2007 were performed off-pump.10 We
note that the recently published results
of a large-scale randomized clinical trial
that favor on-pump over off-pump pro-
cedures may impact this practice pat-
tern, contributing to an increase in the
relative frequency of on-pump proce-
dures.11
Second, Dr McKay was not clear re-
garding the hetastarch formulation
used in our study. Our study examined
Hextend, a formulation of HMW hy-
droxyethyl starch 6% in a buffered
electrolyte dextrose solution. This
composition of the test solution in-
fused is identified on our article’s first
page, and its administration is dis-
cussed in the section describing ran-
domization and sample size. We
inadvertently omitted mentioning this
fluid a second time in the Clinical Pro-
tocol section of our article. We apolo-
gize for any confusion this may have
caused for Dr McKay or other readers.
Participants were randomly assigned
to receive an initial infusion of 1000
mL of Hextend or 1000 mL of albu-
min. Any subsequent infusions of
